MARKET

INNT

INNT

INNOVATE BIOPHARMACEUTICALS INC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4900
+0.0200
+4.26%
Closed 16:00 04/03 EDT
OPEN
0.4800
PREV CLOSE
0.4700
HIGH
0.4900
LOW
0.4101
VOLUME
124.76K
TURNOVER
--
52 WEEK HIGH
2.400
52 WEEK LOW
0.3701
MARKET CAP
20.25M
P/E (TTM)
-0.6137
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average INNT stock price target is 10.00 with a high estimate of 10.00 and a low estimate of 10.00.

EPS

INNT News

More
  • Innovate Biopharmaceuticals Announces Full Year 2019 Financial Results And Strategic And Operational Updates
  • ACCESSWIRE · 03/20 22:30
  • Innovate Biopharmaceuticals Affirms Timeline for Closing of Merger with RDD Pharma Ltd. Closing Expected Around the End of the First Quarter of 2020
  • ACCESSWIRE · 03/11 14:30
  • Advance Auto Parts, Cree among Triangle companies hit as stocks tumble with rising concern over coronavirus
  • American City Business Journals · 02/24 19:59
  • Innovate Biopharmaceuticals Announces Acceptance of Three Abstracts for the 2020 Digestive Disease Week (DDW) Conference
  • ACCESSWIRE · 02/19 12:05

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About INNT

Innovate Biopharmaceuticals, Inc., formerly Monster Digital, Inc., is a clinical stage biotechnology company. The Company is focused on developing novel autoimmune and inflammation therapeutic drugs. Its lead drug candidate, larazotide acetate (INN-202) is a tight junction regulator. Its other products include INN-108 and INN-329 (Secretin). The Company’s INN-108 is a novel small molecule comprised of two active parts with anti- inflammatory and immunodulatory properties coupled through an azo bond. The Company is developing INN-108 as a therapeutic for Ulcerative Colitis (UC). Its Secretin stimulated magnetic resonance cholangiopancreatography (MRCP) is a ionizing, radiation-free assessment of the pancreaticobiliary system. The Company has completed a phase II b clinical trial for celiac disease for INN-202. It is developing INN-108 in a phase II trial for inflammatory bowel disorders, mild to moderate UC and a Gastrointestinal (GI) orphan disease.
More

Webull offers kinds of Innovate Biopharmaceuticals Inc stock information, including NASDAQ:INNT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INNT stock news, and many more online research tools to help you make informed decisions.